AR and prostate carcinoma: Fortunately, with the group of androgen receptor (AR) inhibitors such as apalutamide and enzalutamide, the updated guidelines provide us another highly effective class of which are approved in metastatic hormone sensitive prostate cancer irrespective of risk factors [9,10].